Artificial Hemoglobin Could Become Blood Substitute
WESTPORT, CT (Reuters Health) – A genetically engineered version of hemoglobin may someday serve as the main ingredient in an artificial blood […]
World's Largest Resource for Cardiovascular Perfusion
WESTPORT, CT (Reuters Health) – A genetically engineered version of hemoglobin may someday serve as the main ingredient in an artificial blood […]
We investigated twelve coronary artery specimens without cardiac pathology retrieved from autopsies of neonates 9.3 ± 9.7 days old and compared them to adult specimens with no detected atherosclerosis.
We tested whether administration of FK633, a short-acting glycoprotein IIb/IIIa inhibitor, before median sternotomy and cardiopulmonary bypass was able to interrupt the platelet activation loop and thereby preserve platelet number and function.